SCHEMBL17291348

SCHEMBL17291348

CC(=O)NC(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
RECQL P46063 1/20 0.46
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 6/20 0.45
MAPT P10636 3/20 0.45
HTT P42858 2/20 0.45
CNR2 P34972 1/20 0.45
PKM P14618 1/20 0.44
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
GAA P10253 2/20 0.43
UTS2R Q9UKP6 1/20 0.42
IDO1 P14902 1/20 0.42
ENPP3 O14638 1/20 0.41
ENPP1 P22413 1/20 0.41
ENPP2 Q13822 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17291408 0.93 PKM (0.50) LMNAALDH1A1RXFP1KDM4EKMT2A
SCHEMBL1639850 0.86 TP53 (0.51) LMNAALDH1A1KMT2APKMEGFR
SCHEMBL9961396 0.85 LMNA (0.49) LMNAALDH1A1RECQLKMT2APKM
SCHEMBL10668539 0.83 CNR1 (0.43) LMNAALDH1A1RXFP1KMT2AMAPT
SCHEMBL17291310 0.82 MEN1 (0.48) LMNAALDH1A1RXFP1KMT2AMAPT
SCHEMBL17291386 0.81 ALDH1A1 (0.42) LMNAALDH1A1KMT2APKMTP53
SCHEMBL19732946 0.79 LMNA (0.51) LMNAALDH1A1PKM
SCHEMBL16055972 0.78 UTS2R (0.43) LMNAALDH1A1RXFP1RECQLKDM4E
SCHEMBL20522011 0.78 CNR1 (0.48) LMNAALDH1A1KDM4EKMT2AMAPT
SCHEMBL4256511 0.76 LMNA (0.48) LMNAALDH1A1GAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2935271-B1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-25 EP disclosed
EP-2935271-B1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-25 EP disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-03 US disclosed
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-03 US disclosed
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS CSNK1E, CSNK1A1, CSNK1G1 LMNA 3866/4885ALDH1A1 2235/4885RXFP1 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.